Tharimmune, Inc.Long
Tharimmune (THAR) Soars with Positive EMA Feedback!
Analysis:
Tharimmune (THAR) is showing strong upward momentum on the 15-minute timeframe, setting up for a promising long trade. Recent entry at 5.23, with clear targets ahead:
Key Driver:
Positive regulatory feedback from the European Medicines Agency (EMA) on Tharimmune’s TH104 clinical program for treating chronic pruritus in primary biliary cholangitis has fueled significant investor interest, pushing the stock upward.
Technical Overview:
The chart illustrates a breakout pattern with well-defined support and resistance levels. If momentum continues, the stock is positioned to hit all targets as shown using the Risological Swing Trader as investor confidence builds.
Tharimmune (THAR) is showing strong upward momentum on the 15-minute timeframe, setting up for a promising long trade. Recent entry at 5.23, with clear targets ahead:
- Target 1: 7.31
- Target 2: 10.69
- Target 3: 14.07
- Target 4: 16.16
Key Driver:
Positive regulatory feedback from the European Medicines Agency (EMA) on Tharimmune’s TH104 clinical program for treating chronic pruritus in primary biliary cholangitis has fueled significant investor interest, pushing the stock upward.
Technical Overview:
The chart illustrates a breakout pattern with well-defined support and resistance levels. If momentum continues, the stock is positioned to hit all targets as shown using the Risological Swing Trader as investor confidence builds.
- Indicator used on my charts> Risological.com
- Accurate Entry, Stoploss and Take Profit levels on all charts
- NO Repaint!
- Consistent profits
- Detect and avoid Sideways Market
- Works on all markets and all time frames.
- Accurate Entry, Stoploss and Take Profit levels on all charts
- NO Repaint!
- Consistent profits
- Detect and avoid Sideways Market
- Works on all markets and all time frames.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.